ESMO 2025: Prostate highlights

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC

Rusfertide shows promise for polycythemia vera treatment

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer